Brest Cancer
Conditions
Interventions
cohort 1 (pyrotinib,trastuzumab):none
cohort 2 (trastuzumab,pertuzumab):none
Sponsors
the First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Female patients aged over 18; 2.Immunohistochemistry (IHC) method examination showed: HER2 (3+), or HER2 (2+) with additional positive result for fluorescence in situ hybridization (FISH) examination (It was reviewed and confirmed by the researchers in the experimental center); 3.ECOG score 0-1; 4.Patients with early or locally advanced breast cancer who are planning to receive neoadjuvant therapy; 5.There was no evidence of local / regional recurrence or metastasis; 6.There are traceable medical records during treatment.
Exclusion criteria
Exclusion criteria: 1.Patients who did not sign informed consent; 2.Pregnant and lactating female patients; 3.Any other circumstances in which the investigator believes that the patient is not suitable to participate in the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| ORR (Objective Response Rate);DCR(Disease Control Rate);Safety; | — |
Primary
| Measure | Time frame |
|---|---|
| pCR (pathologic Complete Response); | — |
Countries
China
Contacts
Public ContactQi XiaoWei
the First Affiliated Hospital of Army Medical University
Outcome results
None listed